Table 7.
Studies of previous immunotherapeutics in molluscum contagiosum.
| Author | Treatment type | No. of patients | Average age in years (range) | Therapy dosage | Number of treatments | Complete response (%) | Partial response (%) | Recurrence rate (%) | Most common complication |
|---|---|---|---|---|---|---|---|---|---|
| Maronn et al.7 | Candida | 25 | 5.04 (2–15) | 0.3 mL | 3.07 | 56 | 28 | Unknown | Erythema |
| Enns and Evans 8 | Candida | 29 | 5.14 (2–17) | 0.3 mL | 2.5 (max 6) | 55.2 | 37.9 | 0 | None |
| Gamil et al.9 | Candida | 16 | 6.93 (2–18) | 0.3 mL | 4–5 | 50 | 25 | 0 | Localized edema |
| Bakke and Stein10 | Candida | 1 | 1.58 | Unknown | 3 | 100 | n/a | 0 | None |
| Thomas et al.2 | Candida | 1 | 70 | 0.3 mL | 4 | 100 | n/a | 0 | None |
| Na et al.11 | MMR | 2 | 2 (1–4) | 0.3 mL | 3 | 100 | n/a | 0 | None |
| Chahun et al.12 | MMR | 22 | 19 (6–50) | 0.1–0.3 mL | 3 | 81.8 | 18.2 | 0 | None |
| Khattab and Nasr 13 | PPD | 20 | 13 (3–40) | 0.1 mL | 4 (max 6) | 85 | 15 | 25 | Edema and erythema |
| Sonthalia et al.14 | Vit D | 2 | 13 | 0.2 mL | 2 | 100 | n/a | 0 | None |